Neurohormonal Hypothesis in Heart Failure

Hellenic Journal of Cardiology

Volumn 44, Issue 3, 2003, Pages 195-205

  Tziakas, Dimitrios N ^a   Chalikias, Geogrios K ^a   Xatseras, Dimitrios I ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Heart failure; Model; Neurohormones

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ARGIPRESSIN; BRADYKININ; CYTOKINE; ENDOTHELIN; GROWTH HORMONE; HYDROCORTISONE; KALLIKREIN; NATRIURETIC FACTOR; NEUROHORMONE; NITRIC OXIDE; PROSTAGLANDIN; VASOPRESSIN;

ADRENERGIC SYSTEM; HEART FAILURE; HEART INJURY; HEMODYNAMICS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; THIRST; VASOPRESSIN RELEASE;

EID: 0842333822     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Packer M: The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-254.
2. Ferrara R, Mastrolilli F, Pasanisi G, Censi S, Aiello ND, Fucili A, et al: Neurohormonal modulation in chronic heart failure. Eur Heart J 2002; 4: D3-D11.
3. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 1999; 341: 577-584.
4. Packer M: Pathophysiology of chronic heart failure. Lancet 1992; 340: 88-92.
5. Ferrari R, Ceconi C, Curello S, Visioli O: The neuroendocrine and sympathetic nervous system in congestive heart failure. Eur Heart J 1998; 19: F45-F51.
6. Eisenhofer G, Friberg P, Rundqvist B, Quyyumi A, Lambert G, Kaye DM, et al: Cardiac sympathetic nerve function in congestive heart failure. Circulation 1996; 93: 1677-1676.
7. Dzau VJ, Colucci WS, Hollenburg NK, Williams GH: Relation of the rennin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63: 645-651.
8. Braunwald E: The Denolin Lecture: Congestive heart failure: a half century perspective. Eur Heart J 2001; 22: 825-836.
9. Packer M: Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur Heart J 1995; 16: F4-F6.
10. st edition, Philadelphia, WB Saunders Company.
11. Packer M: How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am Journal of Cardiology 1993; 71: 3C-1C.
12. Mann D: Mechanisms and models in heart failure. A combinatorial approach. Circulation 1999; 100: 999-1008.
13. Anand IS: Neurohormonal modulation in chronic heart failure. Dialogues in Cardiovascular Medicine 1999; 4: 63-73.
14. Anand IS: Pathogenesis of salt and water retention in the congestive heart failure syndrome. In: Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJ. Eds. Heart failure, New York, NY: Churcill Livingstone: 1997: 155-172.
15. Tan LB, Jalil JE, Pick R, Janisky JS, Weber KT: Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69: 1185-1195.
16. Bozkurt B, Kribbs S, Clubb FJ Jr, Michael LH, et al: Pathophysiologically reklevant concentrations of tumour necrosis facto-a promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998; 97: 1382-1391.
17. Cohn JN, Johnson G, Ziesche S, Cobb F, et al: A comparison of enalapril with hydralazine-isosorbide dinitratei in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
18. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left venricular ejection fraction s and congestive heart failure. N Engl J Med 1991; 325: 293-302.
19. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med 1992; 327: 685-691.
20. Packer M, Bristow MR, Cohn JN, Colucci WS, et al: The effect of carvedilol on morbidity abd mortality in patients with heart failure. N Engl J Med 1996; 334: 1350-1355.
21. Chidsey CA, Harrison DC, Braunwald E: Aygmentation of the plasma norepinephrine response to exercise in patients with congestive heart failure. N Eng. J Med 1962; 267: 650-655.
22. Cohn JN, Levine TB, Olivary MT, et al: Plasma norepinehrine as a guide to prognosis in patients with congestive heart failure. N Engl J Med 1984; 311: 819-823.
23. Francis GS, Benedict C, Johnstone DE, et al: Comparison of neuroendocrine activation with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-1729.
24. Jackson G, Gibbs CR, Davies MK, Lip GYH: ABC of heart failure: Pathophysiology. BMJ 2000; 320: 167-170.
25. Anversa P, Olivetti G, Capobasso JM: Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol 1991; 68: 7-16.
26. Pfeffer MA, Braunwald E: Ventricular remodelling after myocardial infarction. Circulation 1990; 181: 1161-1172.
27. Bristow MR: Why does the myocardium fail; insights from basic science. Lancet 1998; 352: I814.
28. Djau VJ: Tissue rennin-angiotensin system in myocardial hypertrophy and failure. Arch Int Med 1993; 153: 937.
29. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson PA: Clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987; 57: 17-22.
30. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris P: Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes and plasma hormones in untreated congestive cardiac failure. Circulation 1989; 80: 299-305.
31. Watkins L Jr, Burton JA, Haber E, Cant JR, Smith F, Barger A: The rennin - angiotensin - aldosterone system in congestive heart failure in conscious dogs. J Clin Invest 1976; 57: 1606-1617.
32. Massie BM: 15 years of heart failure trials: what have we learned? Lancet 1998; 352: I29-I33.
33. Burnier M, Brunner HR: Angiotensin II anatagvnists. Lancet 2000; 355: 637-645.
34. Schrier RW, Better Os: Pathogenesis of ascites formation: mechanism of impaired aldosterone escape in cirrhosis. Eur J Gastroenterol Hepatol 1991; 3: 721-729.
35. De Bold A, Borenstein H, Veress Am Sonnenberg H: A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rat. Life Sci 1981; 28: 89-94.
36. Boomsma F, van den Meiracker AH: Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 2001; 51: 442-449.
37. Calderone A, Takahashi N, Thaik CM, Colucci WS: Atrial natriuretic factor and cyclic guanosine monophosphate modulate cardiac myocyte growth and phenotype. Circulation 1994; 90: 1-317.
38. Itoh H, Pratt RE, Djau VJ: Atrial natriuretic polypepeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990; 86: 1690.
39. Goldsmith SR, Francis GS, Cowley AW, Levine T, Cohn J: Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983; 1: 1385-1390.
40. Pacher R, Stanek B, Hulsmann M, et al: Prognostic impact of big endothelin-1 plasma concetrations compared with invasive haemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996; 27: 633-641.
41. Dzau VJ, Packer M, Lilly LS, Swartz S, Hollenberg N, Williams G: Prostoglandins in severe congestive heart failure. N Engl J Med 1984; 310: 347-352
42. Satoh S, Ohyama Y, Hayashi M: Effects of renal nerve stimulation, norepinephrine and angiotensin II or renal blood flow in relation to release of PG like substances in anesthetized dogs. Arch Int Pharmacodyn Ther 1981; 254: 304-316.
43. Supaporn T, Sanberg SM, Borgeson DD, et al: Blunted cGMP response to agonists and enhanced glomerular 3′-5′ nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int 1996; 50: 1718-1725.
44. Sharma R, Coats A, Anker SD: The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. Intern J Cardiol 2000; 72: 175-186.
45. Adachi H, Nguyen PH, Belardinelli R, Hunter D, Jung T, Wasserman K: Nitric oxide production during exercise in chronic heart failure. Am Heart J 1997; 134: 196-202.
46. Hambrecht R, Adams V, Gielen S, Linke A, Mobius-Winkler S, Yu J, et al: Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. J Am Coll Cardiol 1999; 33: 174-179.
47. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M: Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994; 23: 1427-1433.
48. Levine B, Kalman J, Mayer L, Fillit H, Packer M: Elevated circulating levels of tumor necrosis factor alpha in severe chronic heart failure. N Engl J Med 1990; 323: 236-241.
49. Anker SD, Clark AL, Kemp M, Salsbury C, et al: Tumour necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997; 30: 997-1001.
50. Francis SE, Holden H, Holt CM, Duff GW: Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiology 1998; 30-215-223.
51. Carlstedt F, Lind L, Lindahl B: Proinflammatory cytokines measured in a mixed population on arrival in the emergency department are related to mortality and severity of disease. J Intern Med 1997; 242: 361-365.
52. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF: Interleukin-1 and tumor necrosis factor inhibit cardiac myocyte beta adrenergic responsiveness. Proc Natl Acad Sci. USA 1989; 86: 6753-6757.
53. Mann DL, Young JB: Basic mechanisms in congestive heart failure: Recognizing the role of proinflammatory cytokines. Chest 1994; 105: 897-904.
54. Adams V, Jiang H, Jiangtao Y, Mobius-winkler S, Fiehn E, Linke A, et al: Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol 1999; 33: 959-965.
55. Yokoham T, Vaca L, Rosen RD, Durante W, Hazarika P, Mann DL: Cellular basis for the negative inotropic effects of tumour necrosis factor alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303-2312.
56. Pagani FD, Baker LS, His C, Knox M, Fink MP, Visner MS: Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis alpha in conscious dogs. J Clin Invest. 1992; 90: 389-398.
57. Parissis I: The theory of cytokines in heart failure. Cardiology subjects Hippocration hospital lectures, Athens 2001, 122-133.
58. Sharma JN, Sharma J: Cardiovascular properties of kalikrein kinin system. Curr Med Res Opin 2002; 18: 10-17.
59. Anker SD, Chua TP, Ponikowaki P, et al: Hormonal changes and catabolic - anabolic imbalance in chronic heart failure and their importance in cardiac cachexia. Circulation 1997; 96: 526-534.
60. Wollert KC, Studer R, Doefer K, Schieffer E, et al: Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation 1997; 95: 1910-1917.
61. Sharma R, Anker SD: From tissue wasting to cachexia: changes in peripheral blood flow and skeletal musculature. Eur Heart J 2002; 4: D12-D17.
62. Tajima M, Weinberg EO, Bartunek J, Jin H, et al: Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with post infarction heart failure. Circulation 1999; 99: 127-134.
63. Ferrari R, Panzali AF, Poole-Wilson PA, Anand IS: Plasma immunoreactive CGRP-like activity in treated and untreated congestive heart failure. Lancet 1991; 338: 1084-1084.
64. Fazio S, Sabatini L, Capaldo B, et al: A preliminarystudy of growth hormone in the treatment of dialted cardiomyopathy. N Engl J Med 1996; 334: 809-814.
65. Adamopoulos S, Parissis J, Karatzas D, Georgiades M, et al: Effects of growth hormone administration on plasma levels of proinflammatory cytokines and soluble apoptosis mediators Fas/Fas ligand in patients with dilated cardiomyopathy. Hellenic J Cardiol 2002; 43(4): 332-338.